Phathom Pharmaceuticals Inc (NAS:PHAT)

Q1 2025 Phathom Pharmaceuticals Inc Earnings Call Transcript

May 1, 2025 / 12:00 PM GMT

Release Date Price: $3.36 (-21.68%)

Transcript 10-Q8-K

Key Points

Positve

Phathom Pharmaceuticals Inc (PHAT) reported net revenues of $28.5 million for Q1 2025, with a significant increase in filled prescriptions.
The company has a strong cash position with $212 million in cash and cash equivalents, aiming to reach profitability by 2026 without additional financing.
Phathom Pharmaceuticals Inc (PHAT) has successfully launched its drug, Vuesna, achieving an annualized run rate of $120 million in net revenues within the first 18 months.
The company is implementing cost-saving initiatives to reduce operating expenses to less than $55 million per quarter by Q4 2025.
Phathom Pharmaceuticals Inc (PHAT) has over 120 million lives covered, representing above 80% of the total commercially insured market, and is expanding access through new programs.

Negative

The company is facing potential supply disruptions for one of its H. Pylori combination packs, although it does not anticipate a material impact on revenues.
Phathom Pharmaceuticals Inc (PHAT) is experiencing a shift in volume toward cash pay, impacting revenues despite an increase in prescriptions filled.
The company is halting its broadcast television promotion due to lower ROI, which may affect its market reach and brand awareness.
Phathom Pharmaceuticals Inc (PHAT) is deferring its phase 2 eosinophilic esophagitis study, which could impact its pediatric extension strategies.
There is uncertainty regarding the FDA's decision on the company's citizen's petition, which is critical for its exclusivity timeline and could affect future market dynamics.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHAT.OQ - Phathom Pharmaceuticals Inc
Q1 2025 Phathom Pharmaceuticals Inc Earnings Call
May 01, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to the Fathom Pharmaceuticals first quarter 2025 earnings results call.

At this time, all participants are in a listen-only mode. After the presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.

You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.

Please be advised that today's conference is being recorded. With that, I would like to turn the conference over to Eric Shirelli, Fathom's head of investor relations. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.